Mesa Laboratories (MLAB) Cash & Equivalents (2010 - 2026)

Mesa Laboratories has reported Cash & Equivalents for 16 years, with the latest figure at $29.0 million in Q4 2025.

• Quarterly Cash & Equivalents rose 6.05% year-over-year to $29.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.0 million (up 6.05% YoY) and the FY2025 annual result came in at $27.3 million, down 3.17% from the prior year.
• Cash & Equivalents advanced to $29.0 million in Q4 2025 per MLAB's latest filing, from $20.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $278.3 million in Q3 2021 and troughed at $20.4 million in Q3 2025.
• A 5-year average of $67.8 million and a median of $30.7 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents surged 224.24% in 2021, then slumped 88.37% in 2022.
• Over 5 years, Cash & Equivalents stood at $51.7 million in 2021, then sank by 49.52% to $26.1 million in 2022, then increased by 8.13% to $28.2 million in 2023, then retreated by 3.2% to $27.3 million in 2024, then increased by 6.05% to $29.0 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $29.0 million, $20.4 million, and $21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.